Cannabidiol's prosexual effects in sexually active and sexually inhibited male rats.

Rodríguez-Manzo G.; Canseco-Alba A.; Rojas-Hernández J. · Neuroscience · 2026

**Background & Methods** This preclinical study examined acute and chronic oral cannabidiol (CBD) administration on sexual behavior in male rats, comparing sexually active rats (n=8 per group) as a model of optimal copulatory function versus sexually satiated rats (n=8 per group) as a model of inhibited sexual behavior and reduced sexual motivation. The research characterized dose-dependent effects on sexual parameters including mount latency, intromission latency, and sexual motivation assessed via incentive motivation testing. **Key Findings** • Acute CBD administration produced biphasic, dose-dependent effects on sexual motivation in sexually active males, with effects observed on mount and intromission latencies—parameters linked to sexual motivation and copulatory initiation. • In sexually satiated (sexually inhibited) males, acute CBD treatment reversed the inhibitory state at a specific dose, significantly increasing sexual motivation and performance in sexual incentive motivation testing. • Chronic CBD treatment (14 days) at both low and high doses did not impair sexual behavior expression in sexually active males, indicating absence of negative sexual effects with prolonged use. **Dosage & Administration** Specific dose values and administration protocols are not detailed in the abstract. Treatment consisted of acute dosing and chronic dosing regimens (14 days duration) via oral route; dose-response relationships were evaluated but specific dose ranges are not reported. **Safety & Adverse Effects** No adverse sexual effects or safety concerns were documented in sexually active males receiving chronic CBD treatment. The study did not identify unwanted sexual side effects, though comprehensive toxicological or systemic adverse effect data are not addressed in this summary. **Evidence Quality** This is a preclinical animal model study with inherent limitations regarding extrapolation to human sexual function and behavior. The small sample size (n=8 per group), rodent model, and behavioral assessment methodology limit direct clinical applicability. The study design is sound for preliminary mechanistic investigation but represents early-stage evidence. The authors appropriately suggest that therapeutic potential of CBD for human sexual dysfunctions warrants further clinical exploration, though human efficacy and safety data remain absent. Publication in a peer-reviewed neuroscience journal supports methodological rigor, but clinical translation requires controlled human trials.

More recent cannabis research